The event: FDA approval decision for Adcetris in two cancers -- relapsed or refractory Hodgkin's lymphoma, and relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).
The timeline: The FDA approval decision is expected Aug. 30. Before that, on July 14, the FDA is convening an FDA advisory panel to review Adcetris.
The stakes: Seattle Genetics carries a market value of $2.4 billion, which means investors have not only banked on Adcetris' approval but are also expecting the drug to perform well commercially. Two important firsts hinge on Adcetris: It will be the first approved drug to emerge from Seattle Genetics' lab; and the first drug to validate the company's antibody drug conjugate technology. Adcetris combines the tumor-targeting precision of a monoclonal antibody with the tumor-killing power of chemotherapy.
10 Biotech Trades for Second Half of 2011
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.